Please use this identifier to cite or link to this item: http://localhost:80/xmlui/handle/123456789/14189
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKHALID KHAN, MUHAMMAD-
dc.contributor.authorFARID KHAN, MUHAMMAD-
dc.date.accessioned2022-11-29T05:19:21Z-
dc.date.available2022-11-29T05:19:21Z-
dc.date.issued2008-07-17-
dc.identifier.citationKhan, M. K., & Khan, M. F. (2008). Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. Pakistan Journal of Pharmaceutical Sciences, 21(3).en_US
dc.identifier.issn1011-601X-
dc.identifier.urihttp://142.54.178.187:9060/xmlui/handle/123456789/14189-
dc.description.abstractPharmacokinetics and bioequivalence studies of two brands of ciprofloxacin 500mg (Ciprofloxacin & Ciproxin) were evaluated in 14 healthy male volunteers after oral administration. The drug was analyzed in plasma samples by using HPLC. The peak plasma concentrations of (2.28±0.04 mg/L) and (1.9±0.02 mg/L) was attained in about 1.71 hours and 2.00 hours for both Test and Reference ciprofloxacin, respectively. The mean ± SE values for total area under the curve (AUC) were 11.91±0.26 and 13.11±0.27 h.mg/L for both test and reference tablets respectively. This study indicated that all the differences in bioequivalence parameters for both ciprofloxacin formulations are statistically non-significant, hence both formulations are bioequivalent.en_US
dc.language.isoenen_US
dc.publisherKarachi: Faculty of Pharmacy & Pharmaceutical Sciences, Karachien_US
dc.subjectCiprofloxacin two different formulationsen_US
dc.subjectarea under the curveen_US
dc.subjectpeak plasma levelen_US
dc.subjecttime at which maximum concentration of drugen_US
dc.titleASSESSMENT OF BIOEQUIVALENCE OF CIPROFLOXACIN IN HEALTHY MALE SUBJECTS USING HPLCen_US
dc.typeArticleen_US
Appears in Collections:2006,Part-1

Files in This Item:
File Description SizeFormat 
Paper-17.htm143 BHTMLView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.